|
Home : Unsafe Drugs : Avandia : News Articles : Rosiglitazone labels update cardiovascular risks - - ModernMedicine Rosiglitazone labels update cardiovascular risks - - ModernMedicine
FDA has announced that labeling for rosiglitazone (Avandia, GlaxoSmithKline) has been changed to include information on cardiovascular risks (including death) connected with use of this agent. In addition, labeling has been revised to state that rosiglitazone and medications that contain rosiglitazone should be used by patients already being treated with these agents, or by ...
Avandia Case Evaluation Form
This form is secure and encrypted. More information about secure forms and your privacy here.
|




